Sam Neill says he is cancer-free after nearly five-year battle

Sam Neill says a scan found no cancer in his body after a lymphoma fight that stretched for nearly five years, a result that came only after chemotherapy stopped working and he moved to CAR T-cell therapy. The 78-year-old actor, best known as Alan Grant in the Jurassic Park franchise, called the treatment journey “a miserable business” but said it kept him alive.

Neill said he had lived with a particular form of lymphoma for about five years before the latest update. His cancer was identified as angioimmunoblastic T-cell lymphoma, a rare and often fast-growing form of peripheral T-cell lymphoma that is more common in older people. Swollen glands were first noticed during the Jurassic World Dominion press tour in March 2022, beginning a medical ordeal that quickly moved from diagnosis to aggressive treatment.

The path was not linear. Neill said doctors hit him hard with chemotherapy, but it soon stopped working. Earlier reporting also showed that he later started a new anti-cancer drug that put him into remission for a time, though he still needed ongoing infusions and described the later chemotherapy as “brutal” while saying he was grateful to still be receiving it. The new cancer-free scan marks a major shift after years in which each stage of treatment seemed to buy time rather than deliver certainty.

CAR T-cell therapy became the turning point. The treatment collects a patient’s own immune cells, genetically modifies them, grows them in the laboratory and infuses them back into the body so they can better recognize and attack cancer. Professor Miles Prince described the approach as a way to “turbocharge” immune cells. Neill said it was his only option left when standard chemotherapy failed, and he now says the therapy worked.

The broader significance extends well beyond one actor’s recovery. CAR T-cell therapy remains highly specialized and intensive, and in Australia it has been limited to clinical trials for some conditions. The privately billed cost there has been reported at around $750,000, a number that underscores both the promise of the treatment and the barrier it still poses for many patients. Neill has also been using his experience to push for wider access, a message likely to resonate because he is one of the most recognizable stars in global cinema.

For cancer patients, the language of “cancer-free” does not erase the long monitoring that often follows a difficult blood cancer diagnosis. For Neill, it means a recent scan showed no sign of disease after a treatment path that moved from swollen glands in 2022 to chemotherapy, remission, relapse of resistance, and finally a therapy designed for cases where standard care runs out. He said it is time he did another movie, but his larger story now sits as a rare public example of how rapidly blood-cancer treatment is changing.